Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies.
Active targeting
Cancer targeting
Doxorubicin
Micelleplexes
Nucleic acid delivery
Osteosarcoma
Journal
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
16
07
2019
revised:
09
09
2019
accepted:
31
10
2019
pubmed:
21
1
2020
medline:
21
11
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
Osteosarcoma(OS) represents the main cancer affecting bone tissue, and one of the most frequent in children. In this review we discuss the major pathological hallmarks of this pathology, its current therapeutics, new active biomolecules, as well as the nanotechnology outbreak applied to the development of innovative strategies for selective OS targeting. Small RNA molecules play a role as key-regulator molecules capable of orchestrate different responses in what concerns cancer initiation, proliferation, migration and invasiveness. Frequently associated with lung metastasis, new strategies are urgent to upgrade the therapeutic outcomes and the life-expectancy prospects. Hence, the prominent rise of micelleplexes as multifaceted and efficient structures for nucleic acid delivery and selective drug targeting is revisited here with special emphasis on ligand-mediated active targeting. Future landmarks toward the development of novel nanostrategies for both OS diagnosis and OS therapy improvements are also discussed.
Identifiants
pubmed: 31958514
pii: S0939-6411(20)30017-5
doi: 10.1016/j.ejpb.2019.10.013
pii:
doi:
Substances chimiques
Micelles
0
Nucleic Acids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-106Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.